Luis Juncos
Concepts (458)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 29 | 2023 | 404 | 7.950 |
Why?
| Kidney | 25 | 2023 | 822 | 3.060 |
Why?
| Renal Replacement Therapy | 12 | 2023 | 45 | 2.730 |
Why?
| Renal Insufficiency, Chronic | 7 | 2019 | 182 | 2.370 |
Why?
| Kidney Diseases | 8 | 2021 | 293 | 1.940 |
Why?
| Reperfusion Injury | 9 | 2022 | 117 | 1.890 |
Why?
| Shc Signaling Adaptor Proteins | 5 | 2013 | 27 | 1.890 |
Why?
| Hepatorenal Syndrome | 4 | 2021 | 15 | 1.780 |
Why?
| Renal Dialysis | 9 | 2023 | 193 | 1.710 |
Why?
| Hypertension | 15 | 2017 | 565 | 1.570 |
Why?
| Blood Pressure | 17 | 2023 | 587 | 1.460 |
Why?
| Kidney Tubules, Proximal | 6 | 2013 | 119 | 1.460 |
Why?
| Podocytes | 2 | 2023 | 25 | 1.420 |
Why?
| Sodium | 6 | 2023 | 102 | 1.280 |
Why?
| Kidney Glomerulus | 7 | 2023 | 61 | 1.260 |
Why?
| Sodium Chloride, Dietary | 5 | 2016 | 33 | 1.220 |
Why?
| Oxidative Stress | 10 | 2019 | 958 | 1.190 |
Why?
| Nephrology | 3 | 2021 | 18 | 1.130 |
Why?
| Mineralocorticoid Receptor Antagonists | 2 | 2016 | 4 | 1.130 |
Why?
| Nicotine | 3 | 2013 | 205 | 1.110 |
Why?
| Nitric Oxide | 10 | 2023 | 298 | 1.030 |
Why?
| Critical Illness | 4 | 2022 | 344 | 1.000 |
Why?
| Antihypertensive Agents | 4 | 2013 | 139 | 0.970 |
Why?
| Liver Cirrhosis | 3 | 2021 | 218 | 0.940 |
Why?
| Kidney Tubules, Distal | 5 | 2021 | 17 | 0.880 |
Why?
| Nephrolithiasis | 2 | 2013 | 4 | 0.880 |
Why?
| Animals | 45 | 2022 | 14409 | 0.830 |
Why?
| Angiotensin II | 7 | 2016 | 167 | 0.820 |
Why?
| Reactive Oxygen Species | 6 | 2019 | 491 | 0.810 |
Why?
| Superoxides | 5 | 2016 | 61 | 0.800 |
Why?
| Loop of Henle | 2 | 2019 | 11 | 0.790 |
Why?
| Hemodynamics | 7 | 2022 | 291 | 0.770 |
Why?
| Nitric Oxide Synthase Type I | 6 | 2023 | 22 | 0.760 |
Why?
| Autophagy | 2 | 2020 | 202 | 0.760 |
Why?
| Liver Diseases | 1 | 2021 | 87 | 0.750 |
Why?
| Renal Circulation | 6 | 2021 | 82 | 0.740 |
Why?
| Point-of-Care Systems | 1 | 2021 | 71 | 0.740 |
Why?
| Humans | 51 | 2023 | 54391 | 0.730 |
Why?
| Feedback, Physiological | 7 | 2021 | 19 | 0.720 |
Why?
| Hemodiafiltration | 2 | 2013 | 5 | 0.700 |
Why?
| Natriuretic Agents | 1 | 2019 | 1 | 0.700 |
Why?
| Natriuresis | 1 | 2019 | 7 | 0.690 |
Why?
| Angiotensin I | 1 | 2019 | 15 | 0.690 |
Why?
| Male | 49 | 2021 | 27347 | 0.680 |
Why?
| Testosterone | 3 | 2016 | 119 | 0.670 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2019 | 55 | 0.670 |
Why?
| Cause of Death | 1 | 2019 | 164 | 0.670 |
Why?
| Primary Health Care | 2 | 2013 | 398 | 0.660 |
Why?
| Anticoagulants | 2 | 2020 | 270 | 0.650 |
Why?
| Respiratory Insufficiency | 1 | 2020 | 127 | 0.650 |
Why?
| Proto-Oncogene Proteins | 1 | 2019 | 169 | 0.640 |
Why?
| Receptors, Cannabinoid | 1 | 2017 | 20 | 0.620 |
Why?
| Peptide Fragments | 1 | 2019 | 242 | 0.620 |
Why?
| Hemiarthroplasty | 1 | 2017 | 8 | 0.620 |
Why?
| Aminoglycosides | 1 | 2017 | 22 | 0.620 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 302 | 0.570 |
Why?
| Sodium Chloride | 5 | 2023 | 67 | 0.570 |
Why?
| Sulfenic Acids | 1 | 2015 | 1 | 0.550 |
Why?
| Receptor, Endothelin B | 1 | 2015 | 3 | 0.550 |
Why?
| Prosthesis-Related Infections | 1 | 2017 | 111 | 0.540 |
Why?
| Rats, Sprague-Dawley | 12 | 2016 | 1664 | 0.510 |
Why?
| Nicotinic Agonists | 2 | 2013 | 60 | 0.500 |
Why?
| Mice | 20 | 2022 | 6428 | 0.490 |
Why?
| Cholesterol, HDL | 1 | 2014 | 42 | 0.490 |
Why?
| Endothelin-1 | 1 | 2014 | 30 | 0.490 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 150 | 0.480 |
Why?
| Renin | 2 | 2013 | 23 | 0.470 |
Why?
| Dichloroacetic Acid | 1 | 2013 | 5 | 0.470 |
Why?
| Hemodialysis Solutions | 1 | 2013 | 4 | 0.470 |
Why?
| Diabetic Nephropathies | 1 | 2014 | 77 | 0.460 |
Why?
| Glomerular Filtration Rate | 8 | 2021 | 139 | 0.460 |
Why?
| Cryosurgery | 1 | 2013 | 38 | 0.450 |
Why?
| HSP27 Heat-Shock Proteins | 1 | 2012 | 8 | 0.450 |
Why?
| Cardiovascular Diseases | 3 | 2014 | 476 | 0.450 |
Why?
| Paclitaxel | 1 | 2013 | 103 | 0.450 |
Why?
| Actin Cytoskeleton | 1 | 2012 | 26 | 0.440 |
Why?
| Hypoglycemia | 1 | 2013 | 61 | 0.440 |
Why?
| Rats | 14 | 2016 | 3419 | 0.440 |
Why?
| Arterial Pressure | 3 | 2021 | 50 | 0.430 |
Why?
| Heptanoic Acids | 1 | 2012 | 39 | 0.430 |
Why?
| Pyrroles | 1 | 2012 | 78 | 0.410 |
Why?
| Ischemia | 2 | 2022 | 177 | 0.410 |
Why?
| Azacitidine | 1 | 2011 | 37 | 0.410 |
Why?
| Hydroxamic Acids | 1 | 2011 | 47 | 0.410 |
Why?
| STAT3 Transcription Factor | 1 | 2011 | 88 | 0.410 |
Why?
| Juxtaglomerular Apparatus | 4 | 2017 | 7 | 0.410 |
Why?
| Heart Failure | 2 | 2023 | 541 | 0.400 |
Why?
| NF-E2-Related Factor 2 | 2 | 2023 | 63 | 0.390 |
Why?
| Plasma Exchange | 1 | 2011 | 33 | 0.390 |
Why?
| Glucose | 1 | 2013 | 366 | 0.390 |
Why?
| Heme Oxygenase (Decyclizing) | 1 | 2010 | 8 | 0.380 |
Why?
| Ultrafiltration | 1 | 2010 | 9 | 0.380 |
Why?
| Up-Regulation | 5 | 2021 | 509 | 0.380 |
Why?
| Diuretics | 1 | 2010 | 28 | 0.380 |
Why?
| Vasoconstrictor Agents | 4 | 2021 | 88 | 0.370 |
Why?
| Cisplatin | 1 | 2012 | 351 | 0.370 |
Why?
| Cytochromes c | 4 | 2013 | 41 | 0.360 |
Why?
| GTP Phosphohydrolases | 1 | 2009 | 35 | 0.360 |
Why?
| Blotting, Western | 6 | 2016 | 684 | 0.350 |
Why?
| Weight Gain | 1 | 2010 | 244 | 0.330 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2018 | 232 | 0.330 |
Why?
| Multiple Myeloma | 1 | 2023 | 3049 | 0.320 |
Why?
| Epigenesis, Genetic | 1 | 2011 | 399 | 0.320 |
Why?
| Phosphorylation | 4 | 2013 | 613 | 0.320 |
Why?
| Mice, Inbred C57BL | 8 | 2016 | 2001 | 0.320 |
Why?
| Membrane Glycoproteins | 5 | 2013 | 270 | 0.310 |
Why?
| Kidney Tubules | 5 | 2023 | 99 | 0.300 |
Why?
| Kidney Failure, Chronic | 3 | 2019 | 232 | 0.300 |
Why?
| Glomerulonephritis, Membranous | 2 | 2019 | 37 | 0.300 |
Why?
| Cyclosporine | 2 | 2019 | 66 | 0.300 |
Why?
| Proteinuria | 4 | 2019 | 52 | 0.290 |
Why?
| Inflammation | 3 | 2022 | 678 | 0.290 |
Why?
| Cilia | 2 | 2017 | 9 | 0.290 |
Why?
| Protein Binding | 3 | 2013 | 736 | 0.280 |
Why?
| Treatment Outcome | 7 | 2021 | 5612 | 0.270 |
Why?
| Middle Aged | 18 | 2021 | 13082 | 0.270 |
Why?
| Immunosuppressive Agents | 2 | 2019 | 248 | 0.270 |
Why?
| Mitochondria | 4 | 2013 | 490 | 0.270 |
Why?
| Cyclic N-Oxides | 2 | 2016 | 15 | 0.260 |
Why?
| Prognosis | 5 | 2023 | 2126 | 0.260 |
Why?
| Female | 22 | 2021 | 28471 | 0.250 |
Why?
| Vasoconstriction | 3 | 2011 | 60 | 0.250 |
Why?
| Nitric Oxide Synthase | 4 | 2016 | 102 | 0.240 |
Why?
| Survival Analysis | 3 | 2021 | 736 | 0.240 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2016 | 435 | 0.230 |
Why?
| Water-Electrolyte Imbalance | 1 | 2023 | 17 | 0.230 |
Why?
| Antineoplastic Agents | 1 | 2012 | 1300 | 0.230 |
Why?
| Cells, Cultured | 5 | 2018 | 1737 | 0.230 |
Why?
| Cholestasis | 1 | 2003 | 45 | 0.230 |
Why?
| Iodine | 1 | 2003 | 12 | 0.230 |
Why?
| Poisoning | 1 | 2003 | 31 | 0.230 |
Why?
| Severity of Illness Index | 2 | 2019 | 1082 | 0.230 |
Why?
| Immunoprecipitation | 2 | 2013 | 73 | 0.220 |
Why?
| Creatinine | 2 | 2013 | 169 | 0.210 |
Why?
| Gene Knockdown Techniques | 2 | 2013 | 125 | 0.210 |
Why?
| Vitamin E | 1 | 2003 | 107 | 0.210 |
Why?
| Osmosis | 1 | 2021 | 7 | 0.210 |
Why?
| Luciferases | 2 | 2013 | 57 | 0.210 |
Why?
| Heme Oxygenase-1 | 2 | 2016 | 21 | 0.210 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2021 | 20 | 0.210 |
Why?
| Renal Artery | 2 | 2012 | 40 | 0.210 |
Why?
| Blood Coagulation | 2 | 2013 | 69 | 0.210 |
Why?
| Aldosterone | 2 | 2012 | 8 | 0.210 |
Why?
| Cell Line | 7 | 2015 | 1152 | 0.210 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2022 | 68 | 0.200 |
Why?
| Renin-Angiotensin System | 3 | 2013 | 65 | 0.200 |
Why?
| Aged | 11 | 2019 | 10060 | 0.200 |
Why?
| Promoter Regions, Genetic | 3 | 2013 | 520 | 0.200 |
Why?
| Hypertension, Pregnancy-Induced | 1 | 2021 | 17 | 0.200 |
Why?
| Patient Safety | 2 | 2019 | 121 | 0.190 |
Why?
| Endothelins | 3 | 2005 | 19 | 0.190 |
Why?
| Bile Acids and Salts | 1 | 2021 | 76 | 0.190 |
Why?
| Vasodilator Agents | 2 | 2012 | 111 | 0.190 |
Why?
| Catheterization | 1 | 2021 | 108 | 0.190 |
Why?
| Recurrence | 2 | 2013 | 692 | 0.190 |
Why?
| Obesity | 3 | 2017 | 1203 | 0.180 |
Why?
| Sepsis | 2 | 2013 | 250 | 0.180 |
Why?
| Hemodialysis, Home | 1 | 2019 | 10 | 0.180 |
Why?
| Biomedical Research | 1 | 2023 | 241 | 0.180 |
Why?
| Aorta | 2 | 2011 | 177 | 0.180 |
Why?
| Acute Disease | 2 | 2019 | 403 | 0.170 |
Why?
| Prospective Studies | 7 | 2023 | 2606 | 0.170 |
Why?
| Anti-Bacterial Agents | 2 | 2017 | 825 | 0.170 |
Why?
| Mediastinitis | 2 | 2013 | 5 | 0.170 |
Why?
| Longevity | 1 | 2019 | 89 | 0.170 |
Why?
| Protein Kinases | 1 | 2019 | 88 | 0.170 |
Why?
| Metalloporphyrins | 2 | 2010 | 13 | 0.170 |
Why?
| Preventive Health Services | 1 | 2019 | 52 | 0.170 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 151 | 0.170 |
Why?
| Ultrasonography | 1 | 2021 | 486 | 0.160 |
Why?
| Rats, Wistar | 1 | 2019 | 237 | 0.160 |
Why?
| RNA-Binding Proteins | 1 | 2019 | 136 | 0.160 |
Why?
| Community Health Services | 1 | 2019 | 114 | 0.160 |
Why?
| Young Adult | 6 | 2019 | 4318 | 0.160 |
Why?
| Enzyme Inhibitors | 5 | 2016 | 446 | 0.160 |
Why?
| Adult | 9 | 2020 | 14207 | 0.160 |
Why?
| Oxygen Consumption | 1 | 2019 | 223 | 0.160 |
Why?
| Vasodilation | 2 | 2012 | 106 | 0.150 |
Why?
| Arteriovenous Shunt, Surgical | 2 | 2008 | 38 | 0.150 |
Why?
| Neovascularization, Physiologic | 1 | 2018 | 72 | 0.150 |
Why?
| Gene Dosage | 1 | 2017 | 92 | 0.150 |
Why?
| Quality of Health Care | 1 | 2019 | 219 | 0.150 |
Why?
| Comorbidity | 1 | 2019 | 664 | 0.150 |
Why?
| Bone Cements | 1 | 2017 | 33 | 0.150 |
Why?
| DNA Copy Number Variations | 1 | 2017 | 114 | 0.150 |
Why?
| Graft Occlusion, Vascular | 2 | 2008 | 86 | 0.150 |
Why?
| Hip Fractures | 1 | 2017 | 52 | 0.150 |
Why?
| Stress, Mechanical | 2 | 2015 | 96 | 0.150 |
Why?
| Time Factors | 4 | 2019 | 3210 | 0.150 |
Why?
| Biopsy, Needle | 1 | 2017 | 195 | 0.150 |
Why?
| RNA, Messenger | 5 | 2013 | 1203 | 0.150 |
Why?
| Quality Improvement | 1 | 2019 | 245 | 0.150 |
Why?
| Arterioles | 2 | 2013 | 35 | 0.140 |
Why?
| Serine | 2 | 2013 | 44 | 0.140 |
Why?
| Kidney Medulla | 1 | 2016 | 18 | 0.140 |
Why?
| Antioxidants | 2 | 2016 | 297 | 0.140 |
Why?
| Cell Adhesion Molecules | 2 | 2013 | 87 | 0.140 |
Why?
| DNA, Mitochondrial | 1 | 2017 | 186 | 0.140 |
Why?
| Cannabinoids | 1 | 2017 | 108 | 0.140 |
Why?
| Immunohistochemistry | 2 | 2017 | 1090 | 0.140 |
Why?
| Risk Assessment | 2 | 2019 | 1362 | 0.140 |
Why?
| Interleukin-10 | 1 | 2016 | 106 | 0.140 |
Why?
| Random Allocation | 2 | 2016 | 312 | 0.130 |
Why?
| Infusions, Intravenous | 2 | 2019 | 231 | 0.130 |
Why?
| Receptors, Mineralocorticoid | 2 | 2012 | 6 | 0.130 |
Why?
| Contrast Media | 1 | 2017 | 221 | 0.130 |
Why?
| Hydroxyeicosatetraenoic Acids | 1 | 2015 | 20 | 0.130 |
Why?
| Signal Transduction | 2 | 2020 | 1752 | 0.130 |
Why?
| Epithelial Cells | 3 | 2011 | 255 | 0.120 |
Why?
| Follow-Up Studies | 1 | 2019 | 2390 | 0.120 |
Why?
| Oleic Acid | 1 | 2013 | 7 | 0.120 |
Why?
| Phosphoserine | 1 | 2013 | 8 | 0.120 |
Why?
| Aged, 80 and over | 4 | 2019 | 3431 | 0.120 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 48 | 0.120 |
Why?
| T-Lymphocytes | 1 | 2016 | 374 | 0.120 |
Why?
| Telemetry | 2 | 2003 | 36 | 0.120 |
Why?
| Fumarates | 1 | 2013 | 4 | 0.120 |
Why?
| Pipecolic Acids | 1 | 2013 | 8 | 0.110 |
Why?
| Scedosporium | 1 | 2013 | 5 | 0.110 |
Why?
| Aromatase Inhibitors | 1 | 2013 | 15 | 0.110 |
Why?
| Orchiectomy | 1 | 2013 | 38 | 0.110 |
Why?
| Membrane Proteins | 1 | 2016 | 389 | 0.110 |
Why?
| Antithrombins | 1 | 2013 | 21 | 0.110 |
Why?
| Chromosomes, Mammalian | 1 | 2012 | 5 | 0.110 |
Why?
| Amides | 1 | 2013 | 43 | 0.110 |
Why?
| Quality of Life | 1 | 2019 | 924 | 0.110 |
Why?
| Nitriles | 1 | 2013 | 69 | 0.110 |
Why?
| Oxidative Phosphorylation | 1 | 2013 | 57 | 0.110 |
Why?
| Transcriptional Activation | 1 | 2013 | 134 | 0.110 |
Why?
| Cytokines | 2 | 2016 | 677 | 0.110 |
Why?
| Carbon Monoxide | 1 | 2012 | 37 | 0.110 |
Why?
| Fatty Acids, Unsaturated | 1 | 2012 | 46 | 0.110 |
Why?
| Triazoles | 1 | 2013 | 119 | 0.110 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 142 | 0.110 |
Why?
| Urologic Surgical Procedures | 1 | 2012 | 28 | 0.110 |
Why?
| Hyperlipidemias | 1 | 2012 | 51 | 0.110 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2010 | 206 | 0.110 |
Why?
| Losartan | 1 | 2012 | 28 | 0.100 |
Why?
| Receptors, Androgen | 1 | 2012 | 49 | 0.100 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2012 | 40 | 0.100 |
Why?
| Cholesterol | 1 | 2012 | 155 | 0.100 |
Why?
| Nephrectomy | 1 | 2012 | 93 | 0.100 |
Why?
| Coronary Artery Bypass | 1 | 2013 | 134 | 0.100 |
Why?
| Muscle, Smooth, Vascular | 1 | 2012 | 140 | 0.100 |
Why?
| Mycoses | 1 | 2013 | 162 | 0.100 |
Why?
| Cell Line, Transformed | 1 | 2011 | 88 | 0.100 |
Why?
| Immunity, Cellular | 1 | 2011 | 80 | 0.100 |
Why?
| Drug Therapy, Combination | 1 | 2013 | 426 | 0.100 |
Why?
| Extracorporeal Circulation | 1 | 2011 | 11 | 0.100 |
Why?
| Cerebrovascular Circulation | 1 | 2012 | 137 | 0.100 |
Why?
| Transforming Growth Factor beta1 | 1 | 2011 | 66 | 0.100 |
Why?
| Cotinine | 1 | 2011 | 23 | 0.100 |
Why?
| Kidney Neoplasms | 1 | 2013 | 197 | 0.100 |
Why?
| MAP Kinase Kinase 4 | 1 | 2011 | 34 | 0.100 |
Why?
| Endothelium, Vascular | 1 | 2013 | 288 | 0.100 |
Why?
| Adenoviridae | 1 | 2011 | 58 | 0.100 |
Why?
| Receptors, Adrenergic, alpha-1 | 1 | 2011 | 12 | 0.100 |
Why?
| Malondialdehyde | 1 | 2011 | 63 | 0.100 |
Why?
| Actins | 1 | 2011 | 132 | 0.100 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2008 | 64 | 0.100 |
Why?
| Endothelial Cells | 1 | 2013 | 294 | 0.100 |
Why?
| Transcription Factor AP-1 | 1 | 2011 | 64 | 0.100 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2011 | 116 | 0.100 |
Why?
| Isoenzymes | 3 | 2021 | 177 | 0.100 |
Why?
| Dinoprost | 1 | 2010 | 12 | 0.100 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2008 | 93 | 0.100 |
Why?
| Infusion Pumps, Implantable | 1 | 2010 | 14 | 0.100 |
Why?
| APACHE | 1 | 2010 | 24 | 0.090 |
Why?
| Vascular Resistance | 1 | 2010 | 60 | 0.090 |
Why?
| Case-Control Studies | 4 | 2018 | 1229 | 0.090 |
Why?
| Water-Electrolyte Balance | 1 | 2010 | 40 | 0.090 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2010 | 56 | 0.090 |
Why?
| Binding Sites | 1 | 2011 | 440 | 0.090 |
Why?
| Mesenteric Arteries | 1 | 2010 | 45 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 2 | 2013 | 1476 | 0.090 |
Why?
| Cyclic AMP | 1 | 2010 | 106 | 0.090 |
Why?
| Gene Expression Regulation | 2 | 2015 | 1063 | 0.090 |
Why?
| Microscopy, Fluorescence | 1 | 2011 | 198 | 0.090 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2011 | 181 | 0.090 |
Why?
| Nitrobenzoates | 1 | 2009 | 4 | 0.090 |
Why?
| Ethidium | 1 | 2009 | 7 | 0.090 |
Why?
| Chloride Channels | 1 | 2009 | 29 | 0.090 |
Why?
| Heart Ventricles | 1 | 2012 | 271 | 0.090 |
Why?
| Anemia, Sickle Cell | 1 | 2011 | 94 | 0.090 |
Why?
| Fluorescent Antibody Technique | 1 | 2009 | 141 | 0.090 |
Why?
| Membrane Potentials | 1 | 2009 | 139 | 0.090 |
Why?
| Disease Models, Animal | 6 | 2016 | 1647 | 0.090 |
Why?
| Fluorescent Dyes | 1 | 2009 | 116 | 0.090 |
Why?
| Protein Transport | 1 | 2009 | 195 | 0.090 |
Why?
| Cell Survival | 1 | 2011 | 657 | 0.080 |
Why?
| Atherosclerosis | 1 | 2011 | 249 | 0.080 |
Why?
| Practice Guidelines as Topic | 1 | 2012 | 489 | 0.080 |
Why?
| Quality Indicators, Health Care | 2 | 2019 | 98 | 0.080 |
Why?
| Cell Membrane | 1 | 2009 | 279 | 0.080 |
Why?
| Consensus | 2 | 2019 | 157 | 0.080 |
Why?
| Macrophage Migration-Inhibitory Factors | 1 | 2008 | 4 | 0.080 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 32 | 0.080 |
Why?
| Feedback | 2 | 2023 | 61 | 0.080 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 7 | 0.080 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 25 | 0.080 |
Why?
| Collagenases | 1 | 2008 | 28 | 0.080 |
Why?
| Jugular Veins | 1 | 2008 | 35 | 0.080 |
Why?
| Reproducibility of Results | 2 | 2023 | 1301 | 0.080 |
Why?
| Diet | 1 | 2012 | 598 | 0.080 |
Why?
| Rabbits | 3 | 2015 | 425 | 0.080 |
Why?
| RNA, Small Interfering | 3 | 2015 | 253 | 0.080 |
Why?
| Adolescent | 3 | 2019 | 6900 | 0.080 |
Why?
| Protoporphyrins | 1 | 2006 | 6 | 0.070 |
Why?
| Hemoglobin SC Disease | 1 | 2006 | 6 | 0.070 |
Why?
| Mice, Knockout | 2 | 2021 | 927 | 0.070 |
Why?
| Postoperative Complications | 1 | 2013 | 1035 | 0.070 |
Why?
| Burns | 1 | 2008 | 170 | 0.070 |
Why?
| Military Personnel | 1 | 2008 | 174 | 0.070 |
Why?
| Captopril | 1 | 2005 | 13 | 0.070 |
Why?
| Homeostasis | 2 | 2020 | 223 | 0.070 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 82 | 0.060 |
Why?
| Spin Labels | 2 | 2016 | 7 | 0.060 |
Why?
| Lipid Peroxidation | 1 | 2005 | 132 | 0.060 |
Why?
| Cross-Sectional Studies | 1 | 2010 | 1696 | 0.060 |
Why?
| Sleep Apnea, Obstructive | 1 | 2005 | 65 | 0.060 |
Why?
| Mutation | 1 | 2011 | 1504 | 0.060 |
Why?
| Analysis of Variance | 2 | 2016 | 634 | 0.060 |
Why?
| Sulfonamides | 3 | 2013 | 146 | 0.060 |
Why?
| Ureteral Obstruction | 1 | 2005 | 70 | 0.060 |
Why?
| Cell Count | 2 | 2015 | 181 | 0.060 |
Why?
| Blood Circulation | 1 | 2003 | 20 | 0.060 |
Why?
| Ligation | 1 | 2003 | 64 | 0.060 |
Why?
| Models, Animal | 2 | 2017 | 255 | 0.060 |
Why?
| Restraint, Physical | 1 | 2003 | 21 | 0.060 |
Why?
| Incidence | 2 | 2017 | 1083 | 0.060 |
Why?
| Povidone-Iodine | 1 | 2003 | 5 | 0.060 |
Why?
| Mice, Transgenic | 3 | 2011 | 658 | 0.060 |
Why?
| Blood Pressure Determination | 1 | 2003 | 51 | 0.060 |
Why?
| Therapeutic Irrigation | 1 | 2003 | 27 | 0.060 |
Why?
| Liver Failure | 1 | 2003 | 27 | 0.060 |
Why?
| Mediastinum | 1 | 2003 | 27 | 0.060 |
Why?
| Bile Ducts | 1 | 2003 | 53 | 0.060 |
Why?
| Hypotension | 1 | 2003 | 67 | 0.050 |
Why?
| Lypressin | 1 | 2021 | 2 | 0.050 |
Why?
| Renal Insufficiency | 1 | 2003 | 138 | 0.050 |
Why?
| Kinetics | 1 | 2003 | 692 | 0.050 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 2016 | 21 | 0.050 |
Why?
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 10 | 0.050 |
Why?
| Risk Factors | 3 | 2019 | 3937 | 0.050 |
Why?
| United States | 3 | 2021 | 5208 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2022 | 242 | 0.050 |
Why?
| Acetophenones | 2 | 2011 | 13 | 0.050 |
Why?
| Uterus | 1 | 2021 | 100 | 0.050 |
Why?
| Referral and Consultation | 1 | 2003 | 308 | 0.050 |
Why?
| Genetic Predisposition to Disease | 2 | 2015 | 570 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2019 | 28 | 0.040 |
Why?
| Tertiary Prevention | 1 | 2019 | 1 | 0.040 |
Why?
| Cell Proliferation | 1 | 2023 | 1097 | 0.040 |
Why?
| Treatment Failure | 1 | 2019 | 141 | 0.040 |
Why?
| Fibrosis | 1 | 2020 | 209 | 0.040 |
Why?
| Congresses as Topic | 1 | 2019 | 52 | 0.040 |
Why?
| Remission Induction | 1 | 2019 | 222 | 0.040 |
Why?
| Primary Prevention | 1 | 2019 | 47 | 0.040 |
Why?
| Tomography, X-Ray Computed | 1 | 2005 | 1222 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2016 | 922 | 0.040 |
Why?
| Secondary Prevention | 1 | 2019 | 89 | 0.040 |
Why?
| Professional Role | 1 | 2019 | 88 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 401 | 0.040 |
Why?
| Immunologic Factors | 1 | 2019 | 130 | 0.040 |
Why?
| Polytetrafluoroethylene | 2 | 2008 | 36 | 0.040 |
Why?
| Pandemics | 1 | 2023 | 594 | 0.040 |
Why?
| Administration, Oral | 1 | 2019 | 461 | 0.040 |
Why?
| Electron Transport Complex III | 1 | 2017 | 12 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 674 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2019 | 514 | 0.040 |
Why?
| NADH Dehydrogenase | 1 | 2017 | 17 | 0.040 |
Why?
| Diagnosis, Differential | 1 | 2021 | 1141 | 0.040 |
Why?
| Critical Care | 1 | 2019 | 234 | 0.040 |
Why?
| Receptor, Angiotensin, Type 1 | 2 | 2010 | 61 | 0.040 |
Why?
| Creatine | 1 | 2016 | 38 | 0.040 |
Why?
| Nitrites | 1 | 2016 | 39 | 0.040 |
Why?
| Mississippi | 1 | 2016 | 103 | 0.040 |
Why?
| Nitrates | 1 | 2016 | 49 | 0.040 |
Why?
| Infusions, Parenteral | 1 | 2016 | 21 | 0.040 |
Why?
| Th17 Cells | 1 | 2016 | 26 | 0.040 |
Why?
| Viscosity | 1 | 2015 | 9 | 0.030 |
Why?
| Regional Blood Flow | 2 | 2008 | 121 | 0.030 |
Why?
| Endpoint Determination | 1 | 2015 | 30 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 206 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2015 | 194 | 0.030 |
Why?
| C-Reactive Protein | 1 | 2016 | 159 | 0.030 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 46 | 0.030 |
Why?
| Dogs | 2 | 2006 | 216 | 0.030 |
Why?
| B-Lymphocytes | 1 | 2015 | 176 | 0.030 |
Why?
| Amine Oxidase (Copper-Containing) | 1 | 2013 | 5 | 0.030 |
Why?
| Pregnancy | 1 | 2021 | 2639 | 0.030 |
Why?
| Apoptosis | 1 | 2020 | 1302 | 0.030 |
Why?
| Phosphorylcholine | 1 | 2013 | 18 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2013 | 80 | 0.030 |
Why?
| Animals, Congenic | 1 | 2012 | 4 | 0.030 |
Why?
| Rats, Inbred BN | 1 | 2012 | 21 | 0.030 |
Why?
| Plasmids | 1 | 2013 | 180 | 0.030 |
Why?
| Gene Transfer Techniques | 1 | 2012 | 41 | 0.030 |
Why?
| Middle Cerebral Artery | 1 | 2012 | 39 | 0.030 |
Why?
| Infarction, Middle Cerebral Artery | 1 | 2012 | 44 | 0.030 |
Why?
| Brain Edema | 1 | 2012 | 39 | 0.030 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2011 | 12 | 0.030 |
Why?
| Delayed-Action Preparations | 1 | 2012 | 50 | 0.030 |
Why?
| Autopsy | 1 | 2011 | 52 | 0.030 |
Why?
| S100 Proteins | 1 | 2011 | 41 | 0.030 |
Why?
| Asymptomatic Diseases | 1 | 2011 | 43 | 0.030 |
Why?
| Drug Monitoring | 1 | 2012 | 85 | 0.030 |
Why?
| Arginine | 1 | 2013 | 182 | 0.030 |
Why?
| Immunoglobulins | 1 | 2011 | 89 | 0.030 |
Why?
| Nitrobenzenes | 1 | 2011 | 3 | 0.020 |
Why?
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2011 | 7 | 0.020 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2011 | 20 | 0.020 |
Why?
| Cyclooxygenase 2 | 1 | 2011 | 49 | 0.020 |
Why?
| Furosemide | 1 | 2010 | 9 | 0.020 |
Why?
| Antigens, CD | 1 | 2011 | 242 | 0.020 |
Why?
| Microdissection | 1 | 2010 | 24 | 0.020 |
Why?
| rac GTP-Binding Proteins | 1 | 2010 | 6 | 0.020 |
Why?
| rac1 GTP-Binding Protein | 1 | 2010 | 12 | 0.020 |
Why?
| Antifungal Agents | 1 | 2013 | 363 | 0.020 |
Why?
| Neuropeptides | 1 | 2010 | 48 | 0.020 |
Why?
| Protein Isoforms | 1 | 2010 | 124 | 0.020 |
Why?
| Phenotype | 1 | 2012 | 819 | 0.020 |
Why?
| Gene Expression | 1 | 2012 | 664 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2010 | 158 | 0.020 |
Why?
| Pilot Projects | 1 | 2011 | 807 | 0.020 |
Why?
| Flow Cytometry | 1 | 2011 | 547 | 0.020 |
Why?
| Microcirculation | 1 | 2009 | 89 | 0.020 |
Why?
| Adenosine | 1 | 2009 | 71 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 7 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 531 | 0.020 |
Why?
| Sus scrofa | 1 | 2008 | 39 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 37 | 0.020 |
Why?
| Constriction, Pathologic | 1 | 2008 | 104 | 0.020 |
Why?
| Magnetic Resonance Angiography | 1 | 2008 | 80 | 0.020 |
Why?
| Blood Vessel Prosthesis | 1 | 2008 | 97 | 0.020 |
Why?
| Prosthesis Design | 1 | 2008 | 262 | 0.020 |
Why?
| Kidney Function Tests | 1 | 2006 | 59 | 0.020 |
Why?
| Blood Vessel Prosthesis Implantation | 1 | 2008 | 129 | 0.020 |
Why?
| Thiobarbituric Acid Reactive Substances | 1 | 2005 | 12 | 0.020 |
Why?
| Oxygen | 1 | 2009 | 361 | 0.020 |
Why?
| Isoprostanes | 1 | 2005 | 3 | 0.020 |
Why?
| Rats, Inbred WKY | 1 | 2005 | 29 | 0.020 |
Why?
| Rats, Inbred SHR | 1 | 2005 | 33 | 0.020 |
Why?
| Survival Rate | 1 | 2008 | 954 | 0.020 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2005 | 14 | 0.020 |
Why?
| Radiographic Image Enhancement | 1 | 2005 | 32 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 314 | 0.020 |
Why?
| Probability | 1 | 2005 | 177 | 0.020 |
Why?
| Meclofenamic Acid | 1 | 2003 | 4 | 0.010 |
Why?
| Prostaglandins | 1 | 2003 | 19 | 0.010 |
Why?
| Lipoproteins, LDL | 1 | 2005 | 195 | 0.010 |
Why?
| Angiotensin Receptor Antagonists | 1 | 2003 | 23 | 0.010 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2003 | 44 | 0.010 |
Why?
| Iliac Artery | 1 | 2003 | 41 | 0.010 |
Why?
| Swine | 1 | 2005 | 430 | 0.010 |
Why?
| Cohort Studies | 1 | 2008 | 1546 | 0.010 |
Why?
| Lung | 1 | 2003 | 508 | 0.010 |
Why?
| Retrospective Studies | 1 | 2008 | 6459 | 0.010 |
Why?
|
|
Juncos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|